As Ranbaxy’s Regulatory Woes Persist, Imitrex Exclusivity Threatened
This article was originally published in The Pink Sheet Daily
Executive Summary
No end in sight for FDA’s import ban on drugs manufactured in Ranbaxy’s Dewas, Paonta Sahib facilities; impact on sales will be felt in 2009.